speb/financial-data huggingface dataset:
PPLPHARMA.NS income_statement (annual, 2023-03-31) — Other Non Operating Income Expenses: 1101400000.00
PPLPHARMA.NS income_statement (annual, 2023-03-31) — Other Operating Expenses: 8804400000.00
PPLPHARMA.NS balance_sheet (annual, 2023-03-31) — Other Payable: 126200000.00
PPLPHARMA.NS balance_sheet (annual, 2023-03-31) — Other Properties: 2254800000.00
PPLPHARMA.NS balance_sheet (annual, 2023-03-31) — Other Receivables: 185700000.00
PPLPHARMA.NS balance_sheet (annual, 2023-03-31) — Other Short Term Investments: 4640600000.00
PPLPHARMA.NS income_statement (annual, 2023-03-31) — Other Special Charges: 4800000.00
PPLPHARMA.NS income_statement (annual, 2023-03-31) — Otherunder Preferred Stock Dividend: 0.00
PPLPHARMA.NS balance_sheet (annual, 2023-03-31) — Payables: 12053300000.00
PPLPHARMA.NS balance_sheet (annual, 2023-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 2386400000.00
PPLPHARMA.NS balance_sheet (annual, 2023-03-31) — Prepaid Assets: 5414200000.00
PPLPHARMA.NS income_statement (annual, 2023-03-31) — Pretax Income: -1201500000.00
PPLPHARMA.NS balance_sheet (annual, 2023-03-31) — Properties: 0.00
PPLPHARMA.NS cash_flow (annual, 2023-03-31) — Provisionand Write Offof Assets: -69500000.00
PPLPHARMA.NS cash_flow (annual, 2023-03-31) — Purchase Of Business: -203500000.00
PPLPHARMA.NS cash_flow (annual, 2023-03-31) — Purchase Of Investment: -12233800000.00
PPLPHARMA.NS cash_flow (annual, 2023-03-31) — Purchase Of PPE: -9647500000.00
PPLPHARMA.NS balance_sheet (annual, 2023-03-31) — Raw Materials: 9004600000.00
PPLPHARMA.NS income_statement (annual, 2023-03-31) — Reconciled Cost Of Revenue: 30001800000.00
PPLPHARMA.NS income_statement (annual, 2023-03-31) — Reconciled Depreciation: 6766900000.00
PPLPHARMA.NS income_statement (annual, 2023-03-31) — Rent And Landing Fees: 321000000.00
PPLPHARMA.NS income_statement (annual, 2023-03-31) — Rent Expense Supplemental: 321000000.00
PPLPHARMA.NS cash_flow (annual, 2023-03-31) — Repayment Of Debt: -31862500000.00
PPLPHARMA.NS income_statement (annual, 2023-03-31) — Research And Development: 863600000.00
PPLPHARMA.NS balance_sheet (annual, 2023-03-31) — Restricted Cash: 1119700000.00
PPLPHARMA.NS income_statement (annual, 2023-03-31) — Restructuring And Mergern Acquisition: 69600000.00
PPLPHARMA.NS cash_flow (annual, 2023-03-31) — Sale Of Investment: 8479100000.00
PPLPHARMA.NS cash_flow (annual, 2023-03-31) — Sale Of PPE: 196900000.00
PPLPHARMA.NS income_statement (annual, 2023-03-31) — Selling And Marketing Expense: 3236900000.00
PPLPHARMA.NS income_statement (annual, 2023-03-31) — Selling General And Administration: 5553800000.00
PPLPHARMA.NS balance_sheet (annual, 2023-03-31) — Share Issued: 1221872448.00
PPLPHARMA.NS cash_flow (annual, 2023-03-31) — Short Term Debt Issuance: 18218600000.00
PPLPHARMA.NS cash_flow (annual, 2023-03-31) — Short Term Debt Payments: -14647200000.00
PPLPHARMA.NS income_statement (annual, 2023-03-31) — Special Income Charges: -74400000.00
PPLPHARMA.NS cash_flow (annual, 2023-03-31) — Stock Based Compensation: 0.00
PPLPHARMA.NS balance_sheet (annual, 2023-03-31) — Stockholders Equity: 67735000000.00
PPLPHARMA.NS balance_sheet (annual, 2023-03-31) — Tangible Book Value: 23277700000.00
PPLPHARMA.NS income_statement (annual, 2023-03-31) — Tax Effect Of Unusual Items: -14640000.00
PPLPHARMA.NS income_statement (annual, 2023-03-31) — Tax Provision: 663100000.00
PPLPHARMA.NS income_statement (annual, 2023-03-31) — Tax Rate For Calcs: 0.30
PPLPHARMA.NS cash_flow (annual, 2023-03-31) — Taxes Refund Paid: -1890000000.00
PPLPHARMA.NS balance_sheet (annual, 2023-03-31) — Total Assets: 145225600000.00
PPLPHARMA.NS balance_sheet (annual, 2023-03-31) — Total Capitalization: 101570400000.00
PPLPHARMA.NS balance_sheet (annual, 2023-03-31) — Total Debt: 56370800000.00
PPLPHARMA.NS balance_sheet (annual, 2023-03-31) — Total Equity Gross Minority Interest: 67735000000.00
PPLPHARMA.NS income_statement (annual, 2023-03-31) — Total Expenses: 70803800000.00
PPLPHARMA.NS balance_sheet (annual, 2023-03-31) — Total Liabilities Net Minority Interest: 77490600000.00
PPLPHARMA.NS balance_sheet (annual, 2023-03-31) — Total Non Current Assets: 96870800000.00
PPLPHARMA.NS balance_sheet (annual, 2023-03-31) — Total Non Current Liabilities Net Minority Interest: 39060100000.00
PPLPHARMA.NS income_statement (annual, 2023-03-31) — Total Other Finance Cost: 64700000.00
PPLPHARMA.NS balance_sheet (annual, 2023-03-31) — Total Tax Payable: 35400000.00
PPLPHARMA.NS income_statement (annual, 2023-03-31) — Total Unusual Items: -48800000.00
PPLPHARMA.NS income_statement (annual, 2023-03-31) — Total Unusual Items Excluding Goodwill: -48800000.00
PPLPHARMA.NS balance_sheet (annual, 2023-03-31) — Tradeand Other Payables Non Current: 49800000.00
PPLPHARMA.NS balance_sheet (annual, 2023-03-31) — Treasury Shares Number: 4780520.00
PPLPHARMA.NS balance_sheet (annual, 2023-03-31) — Work In Process: 3347200000.00
PPLPHARMA.NS balance_sheet (annual, 2023-03-31) — Working Capital: 9924300000.00
PPLPHARMA.NS income_statement (annual, 2023-03-31) — Write Off: 0.00
PPLPHARMA.NS income_statement (annual, 2024-03-31) — +Operating Expense: 43856200000.00
PPLPHARMA.NS income_statement (annual, 2024-03-31) — +Total Revenue: 81064100000.00
PPLPHARMA.NS balance_sheet (annual, 2024-03-31) — Accounts Payable: 15383700000.00
PPLPHARMA.NS balance_sheet (annual, 2024-03-31) — Accounts Receivable: 21344300000.00
PPLPHARMA.NS balance_sheet (annual, 2024-03-31) — Accumulated Depreciation: -23635900000.00
PPLPHARMA.NS balance_sheet (annual, 2024-03-31) — Additional Paid In Capital: 47249400000.00
PPLPHARMA.NS balance_sheet (annual, 2024-03-31) — Allowance For Doubtful Accounts Receivable: -1099300000.00
PPLPHARMA.NS balance_sheet (annual, 2024-03-31) — Available For Sale Securities: 208300000.00
PPLPHARMA.NS income_statement (annual, 2024-03-31) — Basic Average Shares: 1281104366.00
PPLPHARMA.NS income_statement (annual, 2024-03-31) — Basic EPS: 0.14
PPLPHARMA.NS cash_flow (annual, 2024-03-31) — Beginning Cash Position: 532300000.00
PPLPHARMA.NS balance_sheet (annual, 2024-03-31) — Buildings And Improvements: 20009600000.00
PPLPHARMA.NS cash_flow (annual, 2024-03-31) — Capital Expenditure: -7120400000.00
PPLPHARMA.NS balance_sheet (annual, 2024-03-31) — Capital Lease Obligations: 1513000000.00
PPLPHARMA.NS balance_sheet (annual, 2024-03-31) — Capital Stock: 13229500000.00
PPLPHARMA.NS balance_sheet (annual, 2024-03-31) — Cash And Cash Equivalents: 3568200000.00
PPLPHARMA.NS balance_sheet (annual, 2024-03-31) — Cash Cash Equivalents And Short Term Investments: 5035300000.00
PPLPHARMA.NS balance_sheet (annual, 2024-03-31) — Cash Financial: 3568200000.00
PPLPHARMA.NS cash_flow (annual, 2024-03-31) — Change In Inventory: -5317500000.00
PPLPHARMA.NS cash_flow (annual, 2024-03-31) — Change In Other Current Assets: 427000000.00
PPLPHARMA.NS cash_flow (annual, 2024-03-31) — Change In Other Current Liabilities: 2306700000.00
PPLPHARMA.NS cash_flow (annual, 2024-03-31) — Change In Payable: 4043000000.00
PPLPHARMA.NS cash_flow (annual, 2024-03-31) — Change In Receivables: -3913900000.00
PPLPHARMA.NS cash_flow (annual, 2024-03-31) — Change In Working Capital: -2343000000.00
PPLPHARMA.NS cash_flow (annual, 2024-03-31) — Changes In Cash: 1481900000.00
PPLPHARMA.NS balance_sheet (annual, 2024-03-31) — Common Stock: 13229500000.00
PPLPHARMA.NS cash_flow (annual, 2024-03-31) — Common Stock Dividend Paid: 0.00
PPLPHARMA.NS balance_sheet (annual, 2024-03-31) — Common Stock Equity: 79113400000.00
PPLPHARMA.NS cash_flow (annual, 2024-03-31) — Common Stock Issuance: 10500000000.00
PPLPHARMA.NS balance_sheet (annual, 2024-03-31) — Construction In Progress: 5657000000.00
PPLPHARMA.NS income_statement (annual, 2024-03-31) — Cost Of Revenue: 32587600000.00
PPLPHARMA.NS balance_sheet (annual, 2024-03-31) — Current Assets: 54644700000.00
PPLPHARMA.NS balance_sheet (annual, 2024-03-31) — Current Capital Lease Obligation: 333100000.00
PPLPHARMA.NS balance_sheet (annual, 2024-03-31) — Current Debt: 20751100000.00
PPLPHARMA.NS balance_sheet (annual, 2024-03-31) — Current Debt And Capital Lease Obligation: 21084200000.00
PPLPHARMA.NS balance_sheet (annual, 2024-03-31) — Current Deferred Taxes Liabilities: 403000000.00
PPLPHARMA.NS balance_sheet (annual, 2024-03-31) — Current Liabilities: 43693000000.00
PPLPHARMA.NS balance_sheet (annual, 2024-03-31) — Current Provisions: 435700000.00
PPLPHARMA.NS cash_flow (annual, 2024-03-31) — Depreciation: 7405600000.00
PPLPHARMA.NS cash_flow (annual, 2024-03-31) — Depreciation And Amortization: 7405600000.00
PPLPHARMA.NS income_statement (annual, 2024-03-31) — Depreciation And Amortization In Income Statement: 7405700000.00
PPLPHARMA.NS income_statement (annual, 2024-03-31) — Depreciation Income Statement: 7405700000.00
PPLPHARMA.NS income_statement (annual, 2024-03-31) — Diluted Average Shares: 1283509687.00
PPLPHARMA.NS income_statement (annual, 2024-03-31) — Diluted EPS: 0.14
PPLPHARMA.NS income_statement (annual, 2024-03-31) — Diluted NI Availto Com Stockholders: 178200000.00
PPLPHARMA.NS cash_flow (annual, 2024-03-31) — Dividends Received Cfi: 220500000.00
PPLPHARMA.NS income_statement (annual, 2024-03-31) — EBIT: 6262400000.00
PPLPHARMA.NS income_statement (annual, 2024-03-31) — EBITDA: 13668100000.00
PPLPHARMA.NS cash_flow (annual, 2024-03-31) — Effect Of Exchange Rate Changes: 177900000.00
PPLPHARMA.NS cash_flow (annual, 2024-03-31) — End Cash Position: 2191900000.00
PPLPHARMA.NS balance_sheet (annual, 2024-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 349400000.00
PPLPHARMA.NS cash_flow (annual, 2024-03-31) — Financing Cash Flow: -4223400000.00
PPLPHARMA.NS balance_sheet (annual, 2024-03-31) — Finished Goods: 4537500000.00
PPLPHARMA.NS cash_flow (annual, 2024-03-31) — Free Cash Flow: 2925000000.00
PPLPHARMA.NS cash_flow (annual, 2024-03-31) — Gain Loss On Investment Securities: 4800000.00
PPLPHARMA.NS cash_flow (annual, 2024-03-31) — Gain Loss On Sale Of PPE: 4600000.00
PPLPHARMA.NS income_statement (annual, 2024-03-31) — General And Administrative Expense: 2627500000.00
PPLPHARMA.NS balance_sheet (annual, 2024-03-31) — Goodwill: 11225500000.00
PPLPHARMA.NS balance_sheet (annual, 2024-03-31) — Goodwill And Other Intangible Assets: 42897700000.00
PPLPHARMA.NS balance_sheet (annual, 2024-03-31) — Gross Accounts Receivable: 22443600000.00
PPLPHARMA.NS balance_sheet (annual, 2024-03-31) — Gross PPE: 71795500000.00
PPLPHARMA.NS income_statement (annual, 2024-03-31) — Gross Profit: 48476500000.00
PPLPHARMA.NS balance_sheet (annual, 2024-03-31) — Hedging Assets Current: 0.00
PPLPHARMA.NS income_statement (annual, 2024-03-31) — Impairment Of Capital Assets: 0.00
PPLPHARMA.NS income_statement (annual, 2024-03-31) — Interest Expense: 4469500000.00
PPLPHARMA.NS income_statement (annual, 2024-03-31) — Interest Expense Non Operating: 4469500000.00
PPLPHARMA.NS income_statement (annual, 2024-03-31) — Interest Income: 119200000.00
PPLPHARMA.NS income_statement (annual, 2024-03-31) — Interest Income Non Operating: 119200000.00
PPLPHARMA.NS cash_flow (annual, 2024-03-31) — Interest Paid Cff: -4696100000.00
PPLPHARMA.NS balance_sheet (annual, 2024-03-31) — Inventory: 21758800000.00
PPLPHARMA.NS balance_sheet (annual, 2024-03-31) — Invested Capital: 124702000000.00
PPLPHARMA.NS cash_flow (annual, 2024-03-31) — Investing Cash Flow: -4340100000.00
PPLPHARMA.NS balance_sheet (annual, 2024-03-31) — Investmentin Financial Assets: 349400000.00
PPLPHARMA.NS balance_sheet (annual, 2024-03-31) — Investments In Other Ventures Under Equity Method: 2053200000.00
PPLPHARMA.NS balance_sheet (annual, 2024-03-31) — Investmentsin Associatesat Cost: 2053200000.00
PPLPHARMA.NS cash_flow (annual, 2024-03-31) — Issuance Of Capital Stock: 10500000000.00
PPLPHARMA.NS cash_flow (annual, 2024-03-31) — Issuance Of Debt: 2401300000.00
PPLPHARMA.NS balance_sheet (annual, 2024-03-31) — Land And Improvements: 4367500000.00
PPLPHARMA.NS balance_sheet (annual, 2024-03-31) — Long Term Capital Lease Obligation: 1179900000.00
PPLPHARMA.NS balance_sheet (annual, 2024-03-31) — Long Term Debt: 24837500000.00
PPLPHARMA.NS balance_sheet (annual, 2024-03-31) — Long Term Debt And Capital Lease Obligation: 26017400000.00
PPLPHARMA.NS cash_flow (annual, 2024-03-31) — Long Term Debt Issuance: 2401300000.00
PPLPHARMA.NS cash_flow (annual, 2024-03-31) — Long Term Debt Payments: -8613000000.00
PPLPHARMA.NS balance_sheet (annual, 2024-03-31) — Long Term Equity Investment: 2053200000.00
PPLPHARMA.NS balance_sheet (annual, 2024-03-31) — Long Term Provisions: 323200000.00
PPLPHARMA.NS balance_sheet (annual, 2024-03-31) — Machinery Furniture Equipment: 41626100000.00
PPLPHARMA.NS income_statement (annual, 2024-03-31) — Minority Interests: 0.00
PPLPHARMA.NS cash_flow (annual, 2024-03-31) — Net Business Purchase And Sale: 0.00
PPLPHARMA.NS cash_flow (annual, 2024-03-31) — Net Common Stock Issuance: 10500000000.00
PPLPHARMA.NS balance_sheet (annual, 2024-03-31) — Net Debt: 42020400000.00
PPLPHARMA.NS cash_flow (annual, 2024-03-31) — Net Foreign Currency Exchange Gain Loss: 482800000.00
PPLPHARMA.NS income_statement (annual, 2024-03-31) — Net Income: 178200000.00
PPLPHARMA.NS income_statement (annual, 2024-03-31) — Net Income Common Stockholders: 178200000.00
PPLPHARMA.NS income_statement (annual, 2024-03-31) — Net Income Continuous Operations: 178200000.00
PPLPHARMA.NS income_statement (annual, 2024-03-31) — Net Income From Continuing And Discontinued Operation: 178200000.00
PPLPHARMA.NS income_statement (annual, 2024-03-31) — Net Income From Continuing Operation Net Minority Interest: 178200000.00
PPLPHARMA.NS cash_flow (annual, 2024-03-31) — Net Income From Continuing Operations: 1198000000.00
PPLPHARMA.NS income_statement (annual, 2024-03-31) — Net Income Including Noncontrolling Interests: 178200000.00
PPLPHARMA.NS income_statement (annual, 2024-03-31) — Net Interest Income: -4365700000.00
PPLPHARMA.NS cash_flow (annual, 2024-03-31) — Net Investment Purchase And Sale: 2586300000.00
PPLPHARMA.NS cash_flow (annual, 2024-03-31) — Net Issuance Payments Of Debt: -9715300000.00
PPLPHARMA.NS cash_flow (annual, 2024-03-31) — Net Long Term Debt Issuance: -6211700000.00
PPLPHARMA.NS income_statement (annual, 2024-03-31) — Net Non Operating Interest Income Expense: -4365700000.00
PPLPHARMA.NS cash_flow (annual, 2024-03-31) — Net Other Financing Charges: 200000.00
PPLPHARMA.NS cash_flow (annual, 2024-03-31) — Net Other Investing Changes: -42500000.00
PPLPHARMA.NS balance_sheet (annual, 2024-03-31) — Net PPE: 48159600000.00
PPLPHARMA.NS cash_flow (annual, 2024-03-31) — Net PPE Purchase And Sale: -7104400000.00
PPLPHARMA.NS cash_flow (annual, 2024-03-31) — Net Short Term Debt Issuance: -3503600000.00
PPLPHARMA.NS balance_sheet (annual, 2024-03-31) — Net Tangible Assets: 36215700000.00
PPLPHARMA.NS balance_sheet (annual, 2024-03-31) — Non Current Deferred Revenue: 1679000000.00
PPLPHARMA.NS balance_sheet (annual, 2024-03-31) — Non Current Deferred Taxes Assets: 3865000000.00
PPLPHARMA.NS balance_sheet (annual, 2024-03-31) — Non Current Deferred Taxes Liabilities: 2291800000.00
PPLPHARMA.NS balance_sheet (annual, 2024-03-31) — Non Current Prepaid Assets: 1148500000.00
PPLPHARMA.NS income_statement (annual, 2024-03-31) — Normalized EBITDA: 14315800000.00
PPLPHARMA.NS income_statement (annual, 2024-03-31) — Normalized Income: 631590000.00
PPLPHARMA.NS cash_flow (annual, 2024-03-31) — Operating Cash Flow: 10045400000.00
PPLPHARMA.NS income_statement (annual, 2024-03-31) — Operating Income: 4620300000.00
PPLPHARMA.NS income_statement (annual, 2024-03-31) — Operating Revenue: 81064100000.00
PPLPHARMA.NS balance_sheet (annual, 2024-03-31) — Ordinary Shares Number: 1318016324.00
PPLPHARMA.NS cash_flow (annual, 2024-03-31) — Other Cash Adjustment Outside Changein Cash: -200000.00
PPLPHARMA.NS balance_sheet (annual, 2024-03-31) — Other Current Assets: 5110200000.00
PPLPHARMA.NS balance_sheet (annual, 2024-03-31) — Other Current Liabilities: 417900000.00
PPLPHARMA.NS balance_sheet (annual, 2024-03-31) — Other Equity Interest: 274700000.00
PPLPHARMA.NS balance_sheet (annual, 2024-03-31) — Other Intangible Assets: 31672200000.00
PPLPHARMA.NS balance_sheet (annual, 2024-03-31) — Other Investments: 349400000.00
PPLPHARMA.NS cash_flow (annual, 2024-03-31) — Other Non Cash Items: 4364500000.00
PPLPHARMA.NS balance_sheet (annual, 2024-03-31) — Other Non Current Assets: 940200000.00
PPLPHARMA.NS balance_sheet (annual, 2024-03-31) — Other Non Current Liabilities: 1679000000.00
PPLPHARMA.NS income_statement (annual, 2024-03-31) — Other Non Operating Income Expenses: 1287200000.00
PPLPHARMA.NS income_statement (annual, 2024-03-31) — Other Operating Expenses: 9784400000.00
PPLPHARMA.NS balance_sheet (annual, 2024-03-31) — Other Payable: 832100000.00
PPLPHARMA.NS balance_sheet (annual, 2024-03-31) — Other Properties: 135300000.00
PPLPHARMA.NS balance_sheet (annual, 2024-03-31) — Other Receivables: 162600000.00
PPLPHARMA.NS balance_sheet (annual, 2024-03-31) — Other Short Term Investments: 1467100000.00
PPLPHARMA.NS income_statement (annual, 2024-03-31) — Other Special Charges: 637900000.00
PPLPHARMA.NS income_statement (annual, 2024-03-31) — Otherunder Preferred Stock Dividend: 0.00
PPLPHARMA.NS balance_sheet (annual, 2024-03-31) — Payables: 16215800000.00
PPLPHARMA.NS balance_sheet (annual, 2024-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 2030000000.00
PPLPHARMA.NS balance_sheet (annual, 2024-03-31) — Prepaid Assets: 5073900000.00
PPLPHARMA.NS income_statement (annual, 2024-03-31) — Pretax Income: 1792900000.00
PPLPHARMA.NS balance_sheet (annual, 2024-03-31) — Properties: 0.00
PPLPHARMA.NS cash_flow (annual, 2024-03-31) — Provisionand Write Offof Assets: -150500000.00
PPLPHARMA.NS cash_flow (annual, 2024-03-31) — Purchase Of Business: 0.00
PPLPHARMA.NS cash_flow (annual, 2024-03-31) — Purchase Of Investment: -16903800000.00
PPLPHARMA.NS cash_flow (annual, 2024-03-31) — Purchase Of PPE: -7120400000.00
PPLPHARMA.NS balance_sheet (annual, 2024-03-31) — Raw Materials: 11963700000.00
PPLPHARMA.NS income_statement (annual, 2024-03-31) — Reconciled Cost Of Revenue: 32587600000.00
PPLPHARMA.NS income_statement (annual, 2024-03-31) — Reconciled Depreciation: 7405600000.00
PPLPHARMA.NS income_statement (annual, 2024-03-31) — Rent And Landing Fees: 315900000.00
PPLPHARMA.NS income_statement (annual, 2024-03-31) — Rent Expense Supplemental: 315900000.00
PPLPHARMA.NS cash_flow (annual, 2024-03-31) — Repayment Of Debt: -8613000000.00
PPLPHARMA.NS income_statement (annual, 2024-03-31) — Research And Development: 1006700000.00
PPLPHARMA.NS balance_sheet (annual, 2024-03-31) — Restricted Cash: 1257400000.00
PPLPHARMA.NS income_statement (annual, 2024-03-31) — Restructuring And Mergern Acquisition: 0.00
PPLPHARMA.NS balance_sheet (annual, 2024-03-31) — Retained Earnings: 9706700000.00
PPLPHARMA.NS cash_flow (annual, 2024-03-31) — Sale Of Investment: 19490100000.00
PPLPHARMA.NS cash_flow (annual, 2024-03-31) — Sale Of PPE: 16000000.00
PPLPHARMA.NS income_statement (annual, 2024-03-31) — Selling And Marketing Expense: 3041300000.00
PPLPHARMA.NS income_statement (annual, 2024-03-31) — Selling General And Administration: 5668800000.00
PPLPHARMA.NS balance_sheet (annual, 2024-03-31) — Share Issued: 1322948130.00
PPLPHARMA.NS cash_flow (annual, 2024-03-31) — Short Term Debt Issuance: 14205700000.00
PPLPHARMA.NS cash_flow (annual, 2024-03-31) — Short Term Debt Payments: -17709300000.00
PPLPHARMA.NS income_statement (annual, 2024-03-31) — Special Income Charges: -643700000.00
PPLPHARMA.NS cash_flow (annual, 2024-03-31) — Stock Based Compensation: 274700000.00
PPLPHARMA.NS balance_sheet (annual, 2024-03-31) — Stockholders Equity: 79113400000.00
PPLPHARMA.NS balance_sheet (annual, 2024-03-31) — Tangible Book Value: 36215700000.00
PPLPHARMA.NS income_statement (annual, 2024-03-31) — Tax Effect Of Unusual Items: -194310000.00
PPLPHARMA.NS income_statement (annual, 2024-03-31) — Tax Provision: 1614700000.00
PPLPHARMA.NS income_statement (annual, 2024-03-31) — Tax Rate For Calcs: 0.30
PPLPHARMA.NS balance_sheet (annual, 2024-03-31) — Taxes Receivable: 12400000.00
PPLPHARMA.NS cash_flow (annual, 2024-03-31) — Taxes Refund Paid: -1568400000.00
PPLPHARMA.NS balance_sheet (annual, 2024-03-31) — Total Assets: 153118100000.00
PPLPHARMA.NS balance_sheet (annual, 2024-03-31) — Total Capitalization: 103950900000.00
PPLPHARMA.NS balance_sheet (annual, 2024-03-31) — Total Debt: 47101600000.00
PPLPHARMA.NS balance_sheet (annual, 2024-03-31) — Total Equity Gross Minority Interest: 79113700000.00
PPLPHARMA.NS income_statement (annual, 2024-03-31) — Total Expenses: 76443800000.00
PPLPHARMA.NS balance_sheet (annual, 2024-03-31) — Total Liabilities Net Minority Interest: 74004400000.00
PPLPHARMA.NS balance_sheet (annual, 2024-03-31) — Total Non Current Assets: 98473400000.00
PPLPHARMA.NS balance_sheet (annual, 2024-03-31) — Total Non Current Liabilities Net Minority Interest: 30311400000.00
PPLPHARMA.NS income_statement (annual, 2024-03-31) — Total Other Finance Cost: 15400000.00
PPLPHARMA.NS balance_sheet (annual, 2024-03-31) — Total Tax Payable: 403000000.00
PPLPHARMA.NS income_statement (annual, 2024-03-31) — Total Unusual Items: -647700000.00
PPLPHARMA.NS income_statement (annual, 2024-03-31) — Total Unusual Items Excluding Goodwill: -647700000.00
PPLPHARMA.NS balance_sheet (annual, 2024-03-31) — Treasury Shares Number: 4931806.00
PPLPHARMA.NS balance_sheet (annual, 2024-03-31) — Work In Process: 5257600000.00
PPLPHARMA.NS balance_sheet (annual, 2024-03-31) — Working Capital: 10951700000.00
PPLPHARMA.NS income_statement (annual, 2024-03-31) — Write Off: 5800000.00
PPLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Accounts Payable: 13357400000.00
PPLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Accounts Receivable: 18271400000.00
PPLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Available For Sale Securities: 219500000.00
PPLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Capital Lease Obligations: 1433200000.00
PPLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Capital Stock: 13231400000.00
PPLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Cash And Cash Equivalents: 2703000000.00
PPLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Cash Cash Equivalents And Short Term Investments: 4527800000.00
PPLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Common Stock: 13231400000.00
PPLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Common Stock Equity: 79071700000.00
PPLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Construction In Progress: 6212500000.00
PPLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Current Assets: 53816600000.00
PPLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Current Capital Lease Obligation: 349400000.00
PPLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Current Debt: 31080800000.00
PPLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Current Debt And Capital Lease Obligation: 31430200000.00
PPLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Current Deferred Taxes Liabilities: 85500000.00
PPLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Current Liabilities: 52373200000.00
PPLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Current Provisions: 509600000.00
PPLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Goodwill: 11304200000.00
PPLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Goodwill And Other Intangible Assets: 41772000000.00
PPLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Gross PPE: 49187500000.00
PPLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Inventory: 24474300000.00
PPLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Invested Capital: 125502600000.00
PPLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Investmentin Financial Assets: 219500000.00
PPLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Investments In Other Ventures Under Equity Method: 1935700000.00
PPLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Long Term Capital Lease Obligation: 1083800000.00
PPLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Long Term Debt: 15350100000.00
PPLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Long Term Debt And Capital Lease Obligation: 16433900000.00
PPLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Long Term Equity Investment: 1935700000.00
PPLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Long Term Provisions: 419000000.00
PPLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Net Debt: 43727900000.00
PPLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Net PPE: 49187500000.00
PPLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Net Tangible Assets: 37299700000.00
PPLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Non Current Deferred Taxes Assets: 3978800000.00
PPLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Non Current Deferred Taxes Liabilities: 2333400000.00
PPLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Non Current Prepaid Assets: 472000000.00
PPLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Ordinary Shares Number: 1319826925.00
PPLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Other Current Assets: 6529400000.00
PPLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Other Current Liabilities: 4268300000.00
PPLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Other Equity Interest: 65840300000.00
PPLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Other Intangible Assets: 30467800000.00
PPLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Other Investments: 370700000.00
PPLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Other Non Current Assets: 664600000.00
PPLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Other Non Current Liabilities: 1786200000.00
PPLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Other Properties: 42975000000.00
PPLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Other Short Term Investments: 1824800000.00
PPLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Payables: 13357400000.00
PPLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Prepaid Assets: 13700000.00
PPLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Share Issued: 1325748130.00
PPLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Stockholders Equity: 79071700000.00
PPLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Tangible Book Value: 37299700000.00
PPLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Taxes Receivable: 13700000.00
PPLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Total Assets: 152417400000.00
PPLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Total Capitalization: 94421800000.00
PPLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Total Debt: 47864100000.00
PPLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Total Equity Gross Minority Interest: 79071700000.00
PPLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Total Liabilities Net Minority Interest: 73345700000.00
PPLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Total Non Current Assets: 98600800000.00
PPLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Total Non Current Liabilities Net Minority Interest: 20972500000.00
PPLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Total Tax Payable: 85500000.00
PPLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Treasury Shares Number: 5921205.00
PPLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Working Capital: 1443400000.00
PPLPHARMA.NS income_statement (quarterly, 2024-12-31) — +Operating Expense: 12574600000.00
PPLPHARMA.NS income_statement (quarterly, 2024-12-31) — +Total Revenue: 22042200000.00
PPLPHARMA.NS income_statement (quarterly, 2024-12-31) — Basic Average Shares: 1226666667.00
PPLPHARMA.NS income_statement (quarterly, 2024-12-31) — Basic EPS: 0.03
PPLPHARMA.NS income_statement (quarterly, 2024-12-31) — Cost Of Revenue: 8058300000.00
PPLPHARMA.NS income_statement (quarterly, 2024-12-31) — Depreciation And Amortization In Income Statement: 1968100000.00
PPLPHARMA.NS income_statement (quarterly, 2024-12-31) — Depreciation Income Statement: 1968100000.00
PPLPHARMA.NS income_statement (quarterly, 2024-12-31) — Diluted Average Shares: 1226666667.00
PPLPHARMA.NS income_statement (quarterly, 2024-12-31) — Diluted EPS: 0.03
PPLPHARMA.NS income_statement (quarterly, 2024-12-31) — Diluted NI Availto Com Stockholders: 36800000.00
PPLPHARMA.NS income_statement (quarterly, 2024-12-31) — EBIT: 1701100000.00
PPLPHARMA.NS income_statement (quarterly, 2024-12-31) — EBITDA: 3669200000.00
PPLPHARMA.NS income_statement (quarterly, 2024-12-31) — Gross Profit: 13983900000.00
PPLPHARMA.NS income_statement (quarterly, 2024-12-31) — Interest Expense: 1033100000.00
PPLPHARMA.NS income_statement (quarterly, 2024-12-31) — Interest Expense Non Operating: 1033100000.00
PPLPHARMA.NS income_statement (quarterly, 2024-12-31) — Minority Interests: 0.00
PPLPHARMA.NS income_statement (quarterly, 2024-12-31) — Net Income: 36800000.00
PPLPHARMA.NS income_statement (quarterly, 2024-12-31) — Net Income Common Stockholders: 36800000.00
PPLPHARMA.NS income_statement (quarterly, 2024-12-31) — Net Income Continuous Operations: 36800000.00
PPLPHARMA.NS income_statement (quarterly, 2024-12-31) — Net Income From Continuing And Discontinued Operation: 36800000.00
PPLPHARMA.NS income_statement (quarterly, 2024-12-31) — Net Income From Continuing Operation Net Minority Interest: 36800000.00
PPLPHARMA.NS income_statement (quarterly, 2024-12-31) — Net Income Including Noncontrolling Interests: 36800000.00
PPLPHARMA.NS income_statement (quarterly, 2024-12-31) — Net Interest Income: -1033100000.00
PPLPHARMA.NS income_statement (quarterly, 2024-12-31) — Net Non Operating Interest Income Expense: -1033100000.00
PPLPHARMA.NS income_statement (quarterly, 2024-12-31) — Normalized EBITDA: 3669200000.00
PPLPHARMA.NS income_statement (quarterly, 2024-12-31) — Normalized Income: 36800000.00
PPLPHARMA.NS income_statement (quarterly, 2024-12-31) — Operating Income: 1409300000.00
PPLPHARMA.NS income_statement (quarterly, 2024-12-31) — Operating Revenue: 22042200000.00
PPLPHARMA.NS income_statement (quarterly, 2024-12-31) — Other Non Operating Income Expenses: 121300000.00
PPLPHARMA.NS income_statement (quarterly, 2024-12-31) — Other Operating Expenses: 5044100000.00
PPLPHARMA.NS income_statement (quarterly, 2024-12-31) — Otherunder Preferred Stock Dividend: 0.00
PPLPHARMA.NS income_statement (quarterly, 2024-12-31) — Pretax Income: 668000000.00
PPLPHARMA.NS income_statement (quarterly, 2024-12-31) — Reconciled Cost Of Revenue: 8058300000.00
PPLPHARMA.NS income_statement (quarterly, 2024-12-31) — Reconciled Depreciation: 1968100000.00
PPLPHARMA.NS income_statement (quarterly, 2024-12-31) — Special Income Charges: 0.00
PPLPHARMA.NS income_statement (quarterly, 2024-12-31) — Tax Effect Of Unusual Items: 0.00
PPLPHARMA.NS income_statement (quarterly, 2024-12-31) — Tax Provision: 631200000.00
PPLPHARMA.NS income_statement (quarterly, 2024-12-31) — Tax Rate For Calcs: 0.30
PPLPHARMA.NS income_statement (quarterly, 2024-12-31) — Total Expenses: 20632900000.00
PPLPHARMA.NS income_statement (quarterly, 2024-12-31) — Total Unusual Items: 0.00
PPLPHARMA.NS income_statement (quarterly, 2024-12-31) — Total Unusual Items Excluding Goodwill: 0.00
PPLPHARMA.NS income_statement (annual, 2025-03-31) — +Operating Expense: 48102200000.00
PPLPHARMA.NS income_statement (quarterly, 2025-03-31) — +Operating Expense: 14808600000.00
PPLPHARMA.NS income_statement (annual, 2025-03-31) — +Total Revenue: 90610000000.00
PPLPHARMA.NS income_statement (quarterly, 2025-03-31) — +Total Revenue: 27540700000.00
PPLPHARMA.NS balance_sheet (annual, 2025-03-31) — Accounts Payable: 15337700000.00
PPLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Accounts Payable: 15337700000.00
PPLPHARMA.NS balance_sheet (annual, 2025-03-31) — Accounts Receivable: 23495200000.00
PPLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Accounts Receivable: 23495200000.00
PPLPHARMA.NS balance_sheet (annual, 2025-03-31) — Accumulated Depreciation: -28092000000.00
PPLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Accumulated Depreciation: -28092000000.00
PPLPHARMA.NS balance_sheet (annual, 2025-03-31) — Additional Paid In Capital: 47372000000.00
PPLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Additional Paid In Capital: 47372000000.00
PPLPHARMA.NS balance_sheet (annual, 2025-03-31) — Allowance For Doubtful Accounts Receivable: -977600000.00
PPLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Allowance For Doubtful Accounts Receivable: -977600000.00
PPLPHARMA.NS balance_sheet (annual, 2025-03-31) — Available For Sale Securities: 207000000.00
PPLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Available For Sale Securities: 207000000.00
PPLPHARMA.NS income_statement (annual, 2025-03-31) — Basic Average Shares: 1323265442.00
PPLPHARMA.NS income_statement (quarterly, 2025-03-31) — Basic Average Shares: 1323275862.00
PPLPHARMA.NS income_statement (annual, 2025-03-31) — Basic EPS: 0.69
PPLPHARMA.NS income_statement (quarterly, 2025-03-31) — Basic EPS: 1.16
PPLPHARMA.NS cash_flow (annual, 2025-03-31) — Beginning Cash Position: 2191900000.00
PPLPHARMA.NS balance_sheet (annual, 2025-03-31) — Buildings And Improvements: 21163400000.00
PPLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Buildings And Improvements: 21163400000.00
PPLPHARMA.NS cash_flow (annual, 2025-03-31) — Capital Expenditure: -6643800000.00
PPLPHARMA.NS balance_sheet (annual, 2025-03-31) — Capital Lease Obligations: 1362000000.00
PPLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Capital Lease Obligations: 1362000000.00
PPLPHARMA.NS balance_sheet (annual, 2025-03-31) — Capital Stock: 13243500000.00
PPLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Capital Stock: 13243500000.00
PPLPHARMA.NS balance_sheet (annual, 2025-03-31) — Cash And Cash Equivalents: 3689800000.00
PPLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Cash And Cash Equivalents: 3689800000.00
PPLPHARMA.NS balance_sheet (annual, 2025-03-31) — Cash Cash Equivalents And Short Term Investments: 3918700000.00
PPLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Cash Cash Equivalents And Short Term Investments: 3918700000.00
PPLPHARMA.NS cash_flow (annual, 2025-03-31) — Cash Dividends Paid: -144700000.00
PPLPHARMA.NS balance_sheet (annual, 2025-03-31) — Cash Equivalents: 0.00
PPLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Cash Equivalents: 0.00
PPLPHARMA.NS balance_sheet (annual, 2025-03-31) — Cash Financial: 3689800000.00
PPLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Cash Financial: 3689800000.00
PPLPHARMA.NS cash_flow (annual, 2025-03-31) — Change In Inventory: -1971200000.00
PPLPHARMA.NS cash_flow (annual, 2025-03-31) — Change In Other Current Assets: -699700000.00
PPLPHARMA.NS cash_flow (annual, 2025-03-31) — Change In Other Current Liabilities: -127700000.00
PPLPHARMA.NS cash_flow (annual, 2025-03-31) — Change In Payable: 182400000.00
PPLPHARMA.NS cash_flow (annual, 2025-03-31) — Change In Receivables: -2334500000.00
PPLPHARMA.NS cash_flow (annual, 2025-03-31) — Change In Working Capital: -4877200000.00
PPLPHARMA.NS cash_flow (annual, 2025-03-31) — Changes In Cash: -259900000.00
PPLPHARMA.NS balance_sheet (annual, 2025-03-31) — Common Stock: 13243500000.00
PPLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Common Stock: 13243500000.00
PPLPHARMA.NS cash_flow (annual, 2025-03-31) — Common Stock Dividend Paid: -144700000.00
PPLPHARMA.NS balance_sheet (annual, 2025-03-31) — Common Stock Equity: 81254100000.00
PPLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Common Stock Equity: 81254100000.00
PPLPHARMA.NS cash_flow (annual, 2025-03-31) — Common Stock Issuance: 0.00
PPLPHARMA.NS balance_sheet (annual, 2025-03-31) — Construction In Progress: 4891200000.00
PPLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Construction In Progress: 4891200000.00
PPLPHARMA.NS income_statement (annual, 2025-03-31) — Cost Of Revenue: 35721300000.00
PPLPHARMA.NS income_statement (quarterly, 2025-03-31) — Cost Of Revenue: 9549800000.00
PPLPHARMA.NS balance_sheet (annual, 2025-03-31) — Current Assets: 57969900000.00
PPLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Current Assets: 57969900000.00
PPLPHARMA.NS balance_sheet (annual, 2025-03-31) — Current Capital Lease Obligation: 370400000.00
PPLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Current Capital Lease Obligation: 370400000.00
PPLPHARMA.NS balance_sheet (annual, 2025-03-31) — Current Debt: 15062000000.00
PPLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Current Debt: 15062000000.00
PPLPHARMA.NS balance_sheet (annual, 2025-03-31) — Current Debt And Capital Lease Obligation: 15432400000.00
PPLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Current Debt And Capital Lease Obligation: 15432400000.00
PPLPHARMA.NS balance_sheet (annual, 2025-03-31) — Current Deferred Taxes Liabilities: 96100000.00
PPLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Current Deferred Taxes Liabilities: 96100000.00
PPLPHARMA.NS balance_sheet (annual, 2025-03-31) — Current Liabilities: 37662700000.00
PPLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Current Liabilities: 37662700000.00
PPLPHARMA.NS balance_sheet (annual, 2025-03-31) — Current Provisions: 428500000.00
PPLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Current Provisions: 428500000.00
PPLPHARMA.NS cash_flow (annual, 2025-03-31) — Depreciation: 8163400000.00
PPLPHARMA.NS cash_flow (annual, 2025-03-31) — Depreciation And Amortization: 8163400000.00
PPLPHARMA.NS income_statement (annual, 2025-03-31) — Depreciation And Amortization In Income Statement: 8163400000.00
PPLPHARMA.NS income_statement (quarterly, 2025-03-31) — Depreciation And Amortization In Income Statement: 2427600000.00
PPLPHARMA.NS income_statement (annual, 2025-03-31) — Depreciation Income Statement: 8163400000.00
PPLPHARMA.NS income_statement (quarterly, 2025-03-31) — Depreciation Income Statement: 2427600000.00
PPLPHARMA.NS income_statement (annual, 2025-03-31) — Diluted Average Shares: 1330683982.00
PPLPHARMA.NS income_statement (quarterly, 2025-03-31) — Diluted Average Shares: 1323275862.00
PPLPHARMA.NS income_statement (annual, 2025-03-31) — Diluted EPS: 0.69
PPLPHARMA.NS income_statement (quarterly, 2025-03-31) — Diluted EPS: 1.16
PPLPHARMA.NS income_statement (annual, 2025-03-31) — Diluted NI Availto Com Stockholders: 911300000.00
PPLPHARMA.NS income_statement (quarterly, 2025-03-31) — Diluted NI Availto Com Stockholders: 1535000000.00
PPLPHARMA.NS cash_flow (annual, 2025-03-31) — Dividends Received Cfi: 463100000.00
PPLPHARMA.NS income_statement (annual, 2025-03-31) — EBIT: 8325700000.00
PPLPHARMA.NS income_statement (quarterly, 2025-03-31) — EBIT: 3764800000.00
PPLPHARMA.NS income_statement (annual, 2025-03-31) — EBITDA: 16489100000.00
PPLPHARMA.NS income_statement (quarterly, 2025-03-31) — EBITDA: 6192400000.00
PPLPHARMA.NS cash_flow (annual, 2025-03-31) — Effect Of Exchange Rate Changes: -108800000.00
PPLPHARMA.NS cash_flow (annual, 2025-03-31) — End Cash Position: 1823200000.00
PPLPHARMA.NS balance_sheet (annual, 2025-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 443000000.00
PPLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 443000000.00
PPLPHARMA.NS cash_flow (annual, 2025-03-31) — Financing Cash Flow: -4408300000.00
PPLPHARMA.NS balance_sheet (annual, 2025-03-31) — Finished Goods: 5970200000.00
PPLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Finished Goods: 5970200000.00
PPLPHARMA.NS cash_flow (annual, 2025-03-31) — Free Cash Flow: 2279200000.00
PPLPHARMA.NS cash_flow (annual, 2025-03-31) — Gain Loss On Investment Securities: -90500000.00
PPLPHARMA.NS cash_flow (annual, 2025-03-31) — Gain Loss On Sale Of PPE: -14400000.00
PPLPHARMA.NS income_statement (annual, 2025-03-31) — General And Administrative Expense: 2561900000.00
PPLPHARMA.NS balance_sheet (annual, 2025-03-31) — Goodwill: 11482100000.00
PPLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Goodwill: 11482100000.00
PPLPHARMA.NS balance_sheet (annual, 2025-03-31) — Goodwill And Other Intangible Assets: 40868500000.00
PPLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Goodwill And Other Intangible Assets: 40868500000.00
PPLPHARMA.NS balance_sheet (annual, 2025-03-31) — Gross Accounts Receivable: 24472800000.00
PPLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Gross Accounts Receivable: 24472800000.00
PPLPHARMA.NS balance_sheet (annual, 2025-03-31) — Gross PPE: 78327000000.00
PPLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Gross PPE: 78327000000.00
PPLPHARMA.NS income_statement (annual, 2025-03-31) — Gross Profit: 54888700000.00
PPLPHARMA.NS income_statement (quarterly, 2025-03-31) — Gross Profit: 17990900000.00
PPLPHARMA.NS balance_sheet (annual, 2025-03-31) — Hedging Assets Current: 133500000.00
PPLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Hedging Assets Current: 133500000.00
PPLPHARMA.NS income_statement (annual, 2025-03-31) — Impairment Of Capital Assets: 501500000.00
PPLPHARMA.NS income_statement (annual, 2025-03-31) — Interest Expense: 4179300000.00
PPLPHARMA.NS income_statement (quarterly, 2025-03-31) — Interest Expense: 1036800000.00
PPLPHARMA.NS income_statement (annual, 2025-03-31) — Interest Expense Non Operating: 4179300000.00
PPLPHARMA.NS income_statement (quarterly, 2025-03-31) — Interest Expense Non Operating: 1036800000.00
PPLPHARMA.NS income_statement (annual, 2025-03-31) — Interest Income: 105800000.00
PPLPHARMA.NS income_statement (annual, 2025-03-31) — Interest Income Non Operating: 105800000.00
PPLPHARMA.NS cash_flow (annual, 2025-03-31) — Interest Paid Cff: -4473800000.00
PPLPHARMA.NS balance_sheet (annual, 2025-03-31) — Inventory: 23127000000.00
PPLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Inventory: 23127000000.00
PPLPHARMA.NS balance_sheet (annual, 2025-03-31) — Invested Capital: 128456800000.00
PPLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Invested Capital: 128456800000.00
PPLPHARMA.NS cash_flow (annual, 2025-03-31) — Investing Cash Flow: -4774600000.00
PPLPHARMA.NS balance_sheet (annual, 2025-03-31) — Investmentin Financial Assets: 443000000.00
PPLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Investmentin Financial Assets: 443000000.00
PPLPHARMA.NS balance_sheet (annual, 2025-03-31) — Investments In Other Ventures Under Equity Method: 2267900000.00
PPLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Investments In Other Ventures Under Equity Method: 2267900000.00
PPLPHARMA.NS balance_sheet (annual, 2025-03-31) — Investmentsin Associatesat Cost: 2267900000.00
PPLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Investmentsin Associatesat Cost: 2267900000.00
PPLPHARMA.NS cash_flow (annual, 2025-03-31) — Issuance Of Capital Stock: 0.00
PPLPHARMA.NS cash_flow (annual, 2025-03-31) — Issuance Of Debt: 2546300000.00
PPLPHARMA.NS balance_sheet (annual, 2025-03-31) — Land And Improvements: 4461600000.00
PPLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Land And Improvements: 4461600000.00
PPLPHARMA.NS balance_sheet (annual, 2025-03-31) — Long Term Capital Lease Obligation: 991600000.00
PPLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Long Term Capital Lease Obligation: 991600000.00
PPLPHARMA.NS balance_sheet (annual, 2025-03-31) — Long Term Debt: 32140700000.00
PPLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Long Term Debt: 32140700000.00
PPLPHARMA.NS balance_sheet (annual, 2025-03-31) — Long Term Debt And Capital Lease Obligation: 33132300000.00
PPLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Long Term Debt And Capital Lease Obligation: 33132300000.00
PPLPHARMA.NS cash_flow (annual, 2025-03-31) — Long Term Debt Issuance: 2546300000.00
PPLPHARMA.NS cash_flow (annual, 2025-03-31) — Long Term Debt Payments: -10645100000.00
PPLPHARMA.NS balance_sheet (annual, 2025-03-31) — Long Term Equity Investment: 2267900000.00
PPLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Long Term Equity Investment: 2267900000.00
PPLPHARMA.NS balance_sheet (annual, 2025-03-31) — Long Term Provisions: 486600000.00
PPLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Long Term Provisions: 486600000.00
PPLPHARMA.NS balance_sheet (annual, 2025-03-31) — Machinery Furniture Equipment: 47560200000.00
PPLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Machinery Furniture Equipment: 47560200000.00
PPLPHARMA.NS income_statement (annual, 2025-03-31) — Minority Interests: 0.00
PPLPHARMA.NS income_statement (quarterly, 2025-03-31) — Minority Interests: 0.00
PPLPHARMA.NS cash_flow (annual, 2025-03-31) — Net Common Stock Issuance: 0.00
PPLPHARMA.NS balance_sheet (annual, 2025-03-31) — Net Debt: 43512900000.00
PPLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Net Debt: 43512900000.00
PPLPHARMA.NS cash_flow (annual, 2025-03-31) — Net Foreign Currency Exchange Gain Loss: 316000000.00
PPLPHARMA.NS income_statement (annual, 2025-03-31) — Net Income: 911300000.00
PPLPHARMA.NS income_statement (quarterly, 2025-03-31) — Net Income: 1535000000.00
PPLPHARMA.NS income_statement (annual, 2025-03-31) — Net Income Common Stockholders: 911300000.00
PPLPHARMA.NS income_statement (quarterly, 2025-03-31) — Net Income Common Stockholders: 1535000000.00
PPLPHARMA.NS income_statement (annual, 2025-03-31) — Net Income Continuous Operations: 911300000.00
PPLPHARMA.NS income_statement (quarterly, 2025-03-31) — Net Income Continuous Operations: 1535000000.00
PPLPHARMA.NS income_statement (annual, 2025-03-31) — Net Income From Continuing And Discontinued Operation: 911300000.00
PPLPHARMA.NS income_statement (quarterly, 2025-03-31) — Net Income From Continuing And Discontinued Operation: 1535000000.00
PPLPHARMA.NS income_statement (annual, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: 911300000.00
PPLPHARMA.NS income_statement (quarterly, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: 1535000000.00
PPLPHARMA.NS cash_flow (annual, 2025-03-31) — Net Income From Continuing Operations: 3417100000.00
PPLPHARMA.NS income_statement (annual, 2025-03-31) — Net Income Including Noncontrolling Interests: 911300000.00
PPLPHARMA.NS income_statement (quarterly, 2025-03-31) — Net Income Including Noncontrolling Interests: 1535000000.00
PPLPHARMA.NS income_statement (annual, 2025-03-31) — Net Interest Income: -4110100000.00
PPLPHARMA.NS income_statement (quarterly, 2025-03-31) — Net Interest Income: -1036800000.00
PPLPHARMA.NS cash_flow (annual, 2025-03-31) — Net Investment Purchase And Sale: 1190600000.00
PPLPHARMA.NS cash_flow (annual, 2025-03-31) — Net Issuance Payments Of Debt: 487100000.00
PPLPHARMA.NS cash_flow (annual, 2025-03-31) — Net Long Term Debt Issuance: -8098800000.00
PPLPHARMA.NS income_statement (annual, 2025-03-31) — Net Non Operating Interest Income Expense: -4110100000.00
PPLPHARMA.NS income_statement (quarterly, 2025-03-31) — Net Non Operating Interest Income Expense: -1036800000.00
PPLPHARMA.NS cash_flow (annual, 2025-03-31) — Net Other Financing Charges: 100000.00
PPLPHARMA.NS cash_flow (annual, 2025-03-31) — Net Other Investing Changes: 163000000.00
PPLPHARMA.NS balance_sheet (annual, 2025-03-31) — Net PPE: 50235000000.00
PPLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Net PPE: 50235000000.00
PPLPHARMA.NS cash_flow (annual, 2025-03-31) — Net PPE Purchase And Sale: -6591300000.00
PPLPHARMA.NS cash_flow (annual, 2025-03-31) — Net Short Term Debt Issuance: 8585900000.00
PPLPHARMA.NS balance_sheet (annual, 2025-03-31) — Net Tangible Assets: 40385600000.00
PPLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Net Tangible Assets: 40385600000.00
PPLPHARMA.NS balance_sheet (annual, 2025-03-31) — Non Current Deferred Revenue: 1756100000.00
PPLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Revenue: 1756100000.00
PPLPHARMA.NS balance_sheet (annual, 2025-03-31) — Non Current Deferred Taxes Assets: 3931300000.00
PPLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Taxes Assets: 3931300000.00
PPLPHARMA.NS balance_sheet (annual, 2025-03-31) — Non Current Deferred Taxes Liabilities: 2483500000.00
PPLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Taxes Liabilities: 2483500000.00
PPLPHARMA.NS balance_sheet (annual, 2025-03-31) — Non Current Prepaid Assets: 1060500000.00
PPLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Non Current Prepaid Assets: 1060500000.00
PPLPHARMA.NS income_statement (annual, 2025-03-31) — Normalized EBITDA: 16885700000.00
PPLPHARMA.NS income_statement (quarterly, 2025-03-31) — Normalized EBITDA: 6192400000.00
PPLPHARMA.NS income_statement (annual, 2025-03-31) — Normalized Income: 1188920000.00
PPLPHARMA.NS income_statement (quarterly, 2025-03-31) — Normalized Income: 1535000000.00
PPLPHARMA.NS cash_flow (annual, 2025-03-31) — Operating Cash Flow: 8923000000.00
PPLPHARMA.NS income_statement (annual, 2025-03-31) — Operating Income: 6786500000.00
PPLPHARMA.NS income_statement (quarterly, 2025-03-31) — Operating Income: 3182300000.00
PPLPHARMA.NS income_statement (annual, 2025-03-31) — Operating Revenue: 90610000000.00
PPLPHARMA.NS income_statement (quarterly, 2025-03-31) — Operating Revenue: 27540700000.00